The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹25.00. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan managed by Nippon Life India Asset Management Limited is an Equity ETF with a passive approach to track Nifty Pharma TRI market exposure. The fund replicates Nifty Pharma TRI through proportionate index holdings, emphasizing fidelity to benchmark with a minimal tracking error of 0.0% and a low expense ratio supportive of passive replication. Portfolio is heavily skewed to Pharmaceuticals & Biotechnology at 99.9% with Sun Pharmaceutical leading at 21.3% and top-five holdings comprising about 56.3%, leaving just 0.1% cash as a modest liquidity buffer. 1Y: +12.9% performance coincides with a negligible tracking error of 0.0%, evidencing efficient replication, while pronounced sector concentration elevates idiosyncratic risk relative to broader equity benchmarks and diversification concerns persist. Operationally the fund reports month-end AUM of ₹1007.5 Cr and monthly average ₹1007.0 Cr, charges a 0.2% expense ratio, and is managed by Jitendra Tolani since Feb 2025 with 19 years' experience.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.21%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,007.47. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the Very High risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.70%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 11.91%. 3-year return: 11.91%. 5-year return: 11.91%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.